However, we found that serum EphA2-NF was a diagnostic biomarker independent of CA19-9, which was detected in more than half of the stage I/II pancreatic cancer cases that were CA19-9 negative (≤2.0 U/mL) and had a higher AUC of 0.91. This evidence concerns the gene EPHA2 and pancreatic neoplasm.